Benefits of glucagon-like peptide-1 receptor agonists versus pioglitazone for cardio-hepatic outcomes: a territory-wide target trial emulation
The effects on incident major adverse liver and cardiovascular outcomes were comparable between GLP1RA and pioglitazone, although the risk of incident HF was lower with GLP1RA. Treatment decisions for T2D patients at risk of adverse cardio-hepatic events should be individualized, considering HF risk and the need for weight loss, which if present, GLP1RA may be preferred.
Authors
- David Tak Wai Lui (ORCID: https://orcid.org/0000-0002-9813-1126)
- Chi‐Ho Lee (ORCID: https://orcid.org/0000-0002-7569-409X)
- Xi Xiong (ORCID: https://orcid.org/0000-0002-9418-7448)
- Carlos King Ho Wong (ORCID: https://orcid.org/0000-0002-6895-6071)
- Ivan Chi Ho Au (ORCID: https://orcid.org/0000-0001-5904-8322)
- Brian Hung‐Hin Lang (ORCID: https://orcid.org/0000-0002-9362-0086)
- Lanlan Li (ORCID: https://orcid.org/0009-0002-5529-5830)
- Wing‐Sun Chow
- Carol Ho‐Yi Fong
Institutions
- Department of Health (CN)
- Chinese University of Hong Kong (HK)
- London School of Hygiene & Tropical Medicine (GB)
- HKU-Pasteur Research Pole (HK)
- Pharmaceutical Biotechnology (Czechia) (CZ)
- Laboratory of Data Discovery for Health (HK)
- University College London (GB)
- University of Hong Kong (HK)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1186/s12933-025-02973-5
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29